Acute Coronary Syndrome Market Insights, Forecast, Growth, Trends 2024-2033

The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.23 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.

The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $12.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.

Market Overview -
Acute coronary syndrome (ACS) refers to a range of clinical manifestations caused by abrupt, decreased blood flow to the heart. Symptoms of ACS include chest pain or discomfort (angina), shortness of breath, dizziness and other signs of heart-related distress. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Rising Prevalence Of Chronic Diseases Fuels Growth In The Acute Coronary Syndrome Market
The increasing prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases is expected to propel the growth of the acute coronary syndrome market going forward. Ischemic heart disease is a chronic disease caused by the obstruction or narrowing of the coronary arteries. The treatment of acute coronary syndrome (ACS) is aimed at promptly relieving symptoms, minimizing heart damage and preventing further complications for patients suffering from various acute coronary syndromes, including ischemic heart disease and vascular diseases. For instance, in August 2022, according to a study published in the Journal of the American College of Cardiology, a US-based organization, all four cardiovascular risk factors are anticipated to rise among the general U.S. population between 2025 and 2060, dyslipidemia increased by 27.6%, and hypertension by 25.1%. The researchers discovered that heart failure (33.4%) and ischemic heart disease (30.7%) had the biggest anticipated increases in rates, followed by heart attack (16.9%) and stroke (33.8%). Therefore, the prevalence of chronic diseases such as coronary artery disease, ischemic heart disease and vascular diseases drives the acute coronary syndrome market.

Competitive Landscape -
Major players in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

Innovative Drug Development Fuels Advancements In Acute Coronary Syndrome Treatment
Major companies operating in the acute coronary syndrome market are developing innovative drugs to treat acute coronary syndrome and sustain their position in the market. The advancements in drug development can increase the efficiency of ACS treatment, reducing the time and resources required for each patient. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, launched Lodoco, which was approved by the Food and Drug Administration (FDA), a US-based government agency. This is the first anti-inflammatory atheroprotective cardiovascular treatment that reduces the risk of heart stroke, coronary revascularization, myocardial infarction (MI) and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Key Segments -

The acute coronary syndrome market covered in this report is segmented -
1) By Type: Non-St-Elevation Myocardial Infarction; St-Elevation Myocardial Infarction; Unstable Angina
2) By Treatment: Medications; Statins; Beta blockers; ACE inhibitors; Anticoagulants; Other Treatment
3) By Diagnosis: Stress Test; Blood Tests; Imaging; Other Diagnosis
4) By Route Of Administration: Oral; Parenteral
5) By End-User: Hospitals; Specialty clinics; Other End User

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.